JBJoan Balcells

Joan Balcells

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Joan Balcells has a total of 157 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Short- and long-term survival of children treated with ventricular assist devices in Spain, based on 15 years’ experience

    by Juan José Menéndez, Amelia Caridad Sánchez-Galindo, Joan Balcells, María Ángeles Tejero-Hernández, Ángela Ferrer-Barba, Emilio Ibiza-Palacios, Constancio Medrano-López, Ferran Gran, Manuel Ángel Frías-Pérez, María García-Vieites, et al.

    To describe the use of ventricular assist devices (VAD) in children in Spain and to identify variables related to survival. This is an observational cohort study of all children younger than 18 years of age who underwent an initial implantation of a VAD at any of the six paediatric heart transplant centers from May 2006 to December 2020. Subjects were identified retrospectively from each hospital's database. Paracorporeal VADs were implanted in 118 children (pulsatile [63%], continuous [30.5%] or both types [5.9%]). Small children (< 0.7 m2 of body surface area) comprised the majority of this cohort (63.3%). Overall, 67% survived to VAD explantation, and 64.9% survived to hospital discharge. Non-central nervous system haemorrhage (39%) and stroke (38.1%) were the most common complications. Body weight 34 μmol/L and bridge to decision strategy, were associated with a higher mortality at hospital discharge and in the long-term. Interagency registry for mechanically assisted circulatory support (INTERMACS) status 1 and cardiac arrest prior to VAD implantation were related to long-term mortality, whereas pre-implantation renal replacement therapy and extracorporeal membrane oxygenation were not related to mortality. In Spain, 67% of the VAD-supported children have been bridged to heart transplantation or to recovery. Body weight lower than 5 Kg, congenital heart disease diagnosis, cholestatic liver dysfunction, bridge to decision as VAD strategy, INTERMACS-1 status and cardiac arrest were pre-implantation variables related to mortality, whereas pre-implantation renal replacement therapy and extracorporeal membrane oxygenation were not.


  • Parvovirus B19 myocarditis in children: a diagnostic and therapeutic approach

    by Roger Esmel-Vilomara, Paola Dolader, Jaume Izquierdo-Blasco, Joan Balcells, Moisés Sorlí, Fuensanta Escudero, Elena Vera, Ferran Gran

    Parvovirus B19 is one of the most frequent causes of pediatric myocarditis, associating high mortality rates or need for cardiac transplantation. The aim of this study is to describe the clinical course of Parvovirus B19 myocarditis in children with emphasis on the role of endomyocardial biopsy and cardiac magnetic resonance, and the use of an innovative therapeutic strategy. Eleven patients and 12 episodes of polymerase chain reaction (PCR)-confirmed Parvovirus B19 myocarditis were prospectively collected for 14 years. Diagnosis was confirmed either histopathologically or by magnetic resonance. A life-threatening clinical presentation is described, similar to previous series, but with 83.3% overall survival without transplantation. We also present a case of recurrent myocarditis, which is extraordinarily rare. Electrocardiographic patterns presented chiefly peaked p waves, low QRS voltages, and negative T waves on inferior or lateral leads. Endomyocardial biopsy is the gold standard diagnostic test; alternatively magnetic resonance could be a useful diagnostic tool. A good concordance between myocardial and blood PCRs was observed. Seven patients received treatment with corticosteroids and beta interferon and all underwent a significant cardiac function improvement. Conclusion: A severe clinical presentation is reported, similar to previous reports but with better outcomes. Endomyocardial biopsy is the gold standard diagnostic test; alternatively magnetic resonance may be used. Both blood and myocardium PCR can be used in children to establish the microbiological etiology. Steroids with IFNß could be a useful therapeutic option, although further multicenter studies are needed to confirm these results. What is Known: • Parvovirus B19 is one of the most frequent causes of myocarditis in children. It is associated with a fulminant clinical presentation. • Endomyocardial biopsy is the gold standard diagnostic test but it is an invasive procedure. What is New: • Myocarditis may recur in pediatrics, even it is extraordinarily rare. • IFNβ with steroids may be a useful therapeutic option to improve the outcomes.


  • Open Access

    Influenza-Associated Disseminated Aspergillosis in a 9-Year-Old Girl Requiring ECMO Support

    by Natalia Mendoza-Palomar, Susana Melendo-Pérez, Joan Balcells, Jaume Izquierdo-Blasco, Maria Teresa Martín-Gómez, Monica Velasco-Nuño, Jacques G. Rivière, Pere Soler-Palacin

    A previously healthy 9-year-old girl developed fulminant myocarditis due to severe influenza A infection complicated with methicillin-resistant Staphylococcus aureus pneumonia, requiring extracorporeal membrane oxygenation (ECMO) support. Twelve days after admission, Aspergillus fumigatus was isolated in tracheal aspirate, and 12 h later she suddenly developed anisocoria. Computed tomography (CT) of the head showed fungal brain lesions. Urgent decompressive craniectomy with lesion drainage was performed; histopathology found hyphae in surgical samples, culture-positive for Aspergillus fumigatus (susceptible to azoles, echinocandins, and amphotericin B). Extension workup showed disseminated aspergillosis. After multiple surgeries and combined antifungal therapy (isavuconazole plus liposomal amphotericin B), her clinical course was favorable. Isavuconazole therapeutic drug monitoring was performed weekly. Extensive immunological study ruled out primary immunodeficiencies. Fluorine-18 fluorodeoxyglucose positron emission tomography/CT (18F-FDG PET/CT) follow-up showed a gradual decrease in fungal lesions. Influenza-associated pulmonary aspergillosis is well-recognized in critically ill adult patients, but pediatric data are scant. Clinical features described in adults concur with those of our case. Isavuconazole, an off-label drug in children, was chosen because our patient had severe renal failure. To conclude, influenza-associated pulmonary aspergillosis is uncommon in children admitted to intensive care for severe influenza, but pediatricians should be highly aware of this condition to enable prompt diagnosis and treatment.


  • Differences between genetic dilated cardiomyopathy and myocarditis in children presenting with severe cardiac dysfunction

    by Ferran Gran, Andrea Fidalgo, Paola Dolader, Marta Garrido, Alexandra Navarro, Jaume Izquierdo-Blasco, Joan Balcells, Marta Codina-Sola, Paula Fernandez-Alvarez, Anna Sabaté-Rotés, et al.

    The online version contains supplementary material available at 10.1007/s00431-021-04175-z.


  • Open Access

    Transient upper limb ischaemia during veno-arterial extracorporeal membrane oxygenation in a child

    by Jaume Izquierdo-Blasco, Lucía Riaza, Montse Pujol, Ferran Gran, Joaquín Fernández-Doblas, Joaquín Pérez-Andreu, Raul F Abella, Joan Balcells

    Neck cannulation is the most common cannulation strategy performed to provide veno-arterial extracorporeal membrane oxygenation support in paediatric patients, especially in small children. Upper limb ischaemia is a rare complication of neck cannulation and is likely caused by arterial cannula malposition. We describe a case of right arm ischaemia caused by extrinsic compression of the right subclavian artery by the venous drainage cannula inserted through the right internal jugular vein. Upper limb hypoperfusion was resolved immediately after changing the venous drainage cannula from the right jugular vein to the right femoral vein.

  • Top Cited Papers

    Pre‐eclampsia‐like syndrome induced by severe COVID‐19: a prospective observational study

    by Manel Mendoza, Itziar Garcia‐Ruiz, Nerea Maiz, Carlota Rodo, Pablo Garcia‐Manau, Berta Serrano, Rosa Maria Lopez‐Martinez, Joan Balcells, Nuria Fernandez‐Hidalgo, Elena Carreras, et al.

    Objectives: To investigate the incidence of clinical, ultrasonographic and biochemical findings related to pre‐eclampsia (PE) in pregnancies with COVID‐19, and to assess their accuracy to differentiate between PE and the PE‐like features associated with COVID‐19.Design: A prospective, observational study.Setting: Tertiary referral hospital.Participants: Singleton pregnancies with COVID‐19 at >20+0 weeks.Methods: Forty‐two consecutive pregnancies were recruited and classified into two groups: severe and non‐severe COVID‐19, according to the occurrence of severe pneumonia. Uterine artery pulsatility index (UtAPI) and angiogenic factors (soluble fms‐like tyrosine kinase‐1/placental growth factor [sFlt‐1/PlGF]) were assessed in women with suspected PE.Main outcome measures: Incidence of signs and symptoms related to PE, such as hypertension, proteinuria, thrombocytopenia, elevated liver enzymes, abnormal UtAPI and increased sFlt‐1/PlGF.Results: Thirty‐four cases were classified as non‐severe and 8 as severe COVID‐19. Five (11.9%) women presented signs and symptoms of PE, all five being among the severe COVID‐19 cases (62.5%). However, abnormal sFlt‐1/PlGF and UtAPI could only be demonstrated in one case. One case remained pregnant after recovery from severe pneumonia and had a spontaneous resolution of the PE‐like syndrome.Conclusions: Pregnant women with severe COVID‐19 can develop a PE‐like syndrome that might be distinguished from actual PE by sFlt‐1/PlGF, LDH and UtAPI assessment. Healthcare providers should be aware of its existence and monitor pregnancies with suspected pre‐eclampsia with caution.Tweetable This study shows that a pre‐eclampsia‐like syndrome could be present in some pregnancies with severe COVID‐19.


  • Parvovirus B19 Myocarditis: Looking Beyond the Heart

    by Jaume Izquierdo-Blasco, María Teresa Salcedo Allende, Maria Gemma Codina Grau, Ferran Gran, Elena Martínez Sáez, Joan Balcells

    Human parvovirus B19 represents the most common etiology of myocarditis in the pediatric population. Although it usually causes a benign exanthematic viral infection, parvovirus B19 may also present as disseminated disease with tropism for the myocardium, causing heart failure with high mortality. We present the case of a 2-year-old patient with fulminating acute myocarditis in whom the histological, immunophenotypic, and microbiological findings in necropsy showed multiorgan involvement caused by parvovirus B19. The autopsy revealed changes due to infection with parvovirus B19 as well as hypoxic-ischemic and secondary autoimmune changes. Medullary aplasia was observed, transmural lymphocyte myocarditis, lymphocytosis in the dermis with endothelial cells positive for parvovirus B19 in immunohistochemistry, cholestatic hepatitis due to ischemia and autoimmune hepatitis, lymphadenitis, and signs of hemophagocytosis. We also found hypoxic-ischemic encephalopathy.


  • Open Access

    Cobalamin disorder CblC presenting with hemolytic uremic syndrome and pulmonary hypertension

    by Zuriñe Martínez de Compañón, Miriam Poblet-Puig, Griselda Vallès, Mireia Del Toro, Ramón Vilalta, Antonio Moreno, Joan Balcells


  • Impact of the implementation of an interdisciplinary infection control program to prevent surgical wound infection in pediatric heart surgery

    by Jaume Izquierdo-Blasco, Magda Campins-Martí, Pere Soler-Palacín, Joan Balcells, Raul Abella, Ferran Gran, Félix Castillo, Rosario Nuño, Joan Sanchez-De-Toledo

    Surgical site infection (SSI) remains a major source of morbidity, mortality, and increased health care costs in children undergoing heart surgery. The aim of this study was to assess the effectiveness of an intervention program designed to reduce the high incidence of SSI observed at our center in pediatric patients. An interdisciplinary infection control program including pre-, intra-, and postoperative measures was introduced for children undergoing heart surgery with cardiopulmonary bypass. We conducted a quasi-experimental interventional study comparing a pre-intervention cohort (June 2009 to March 2010) and a post-intervention cohort (July 2011 to July 2012). A significant drop in SSI incidence from 10.9 % (95 % CI 4.7–18.8) to 1.92 % (95 % CI 0.4–5.52) was observed. Variables significantly associated with infection risk were median age (14 days in infected vs 2.3 years in non-infected patients; p < 0.01), hospitalization unit (10.3 % SSI cumulative incidence in the neonatal intensive care unit vs 0 cases in the pediatric intensive care unit; p < 0.01), and median preoperative hospital stay (14 days in infected vs 1 day in non-infected patients; p = 0.03). Conclusions: The implementation of a new intervention program was associated with an 82 % (95 % CI 34–94) reduction in SSI incidence in children undergoing heart surgery at our center.